Drug Trial Radar · NCT07883538
Comparison of Topical Clascoterone 1% Cream Versus Adapalene 0.1% Cream in the Treatment of Mild-to-Moderate Acne Vulgaris
Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
130
Planned (sponsor's estimate)
Start
Oct 8, 2026
Primary completion
Apr 30, 2027
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- Pak Emirates Military HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 20, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will compare the effectiveness and safety of topical clascoterone 1% cream and adapalene 0.1% cream in patients with mild-to-moderate acne vulgaris. Acne is a common skin condition that causes blackheads, whiteheads, pimples, and inflammation. A total of 130 eligible participants aged 12-40 years will be enrolled in a randomized controlled trial at the Dermatology Outpatient Department of Pak Emirates Military Hospital, Rawalpindi, Pakistan. Participants will be randomly assigned to one of two treatment groups. Group A will receive clascoterone 1% cream applied twice daily, while Group B will receive adapalene 0.1% cream applied once daily at night. Treatment will continue for 12 weeks. Participants will be assessed at baseline and during follow-up visits at Weeks 4, 8, and 12. Treatment response will be evaluated using the Investigator's Global Assessment (IGA) score and acne lesion counts. Treatment success will be defined as an IGA score of 0 (clear) or 1 (almost clear), with at least a two-grade improvement from baseline at Week 12. Adverse effects, treatment compliance, and patient satisfaction will also be assessed. The study aims to compare the efficacy and tolerability of both treatments in patients with mild-to-moderate acne vulgaris.
Conditions
- Acne Vulgaris
Interventions
Clascoterone 1% creamDrug
Clascoterone 1% cream applied topically to the affected facial area twice daily for 12 weeks. Participants will receive standard advice regarding gentle cleansing, moisturizer use, avoidance of picking or squeezing acne lesions, and daytime sunscreen use.
Adapalene 0.1% creamDrug
Adapalene 0.1% cream applied topically to the affected facial area once daily at night for 12 weeks. Participants will receive the same standard advice regarding gentle cleansing, moisturizer use, avoidance of picking or squeezing acne lesions, and daytime sunscreen use.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment success at week 12Time frame: 12 weeks after initiation of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pak Emirates Military Hospital
Rawalpindi, Punjab Province, Pakistan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.